Early detection of cancer via screening has been shown to lead to improved survival for several common malignancies. However, screening comes with significant risks and expenses. One important issue faced by all screening tests is detecting as many cancers as possible while minimizing identification of false positives. False positive screening results induce anxiety in patients and their families, require additional expensive tests, and may result in harm if a follow-up study leads to a complication. We propose to develop a novel, genomic approach for cancer screening that leverages insights gained from high throughput re-sequencing of cancer genomes. We will develop this method in the context of lung cancer, since it is the number one cause of cancer deaths and since low dose computed tomography (CT) screening has recently been shown to produce significant survival benefits in high-risk patients. However, ~95% of positive screening results from low dose CT lung cancer screenings are false positives and so improvements are clearly needed. This proposal describes our plan to develop, optimize, and test our method. We will perform both pre-clinical and clinical evaluations and will test our approach in multiple settings, includig as a secondary screening procedure for differentiating between true positive and false positive screening results and as a primary screening modality. Importantly, the method is readily extendable to any cancer for which high throughout sequencing data are available and we envision ultimately being able to screen for most common cancers using a single assay.

National Institute of Health (NIH)
National Cancer Institute (NCI)
NIH Director’s New Innovator Awards (DP2)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-MOSS-C (56))
Program Officer
Mietz, Judy
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Stanford University
Schools of Medicine
United States
Zip Code
Newman, Aaron M; Lovejoy, Alexander F; Klass, Daniel M et al. (2016) Integrated digital error suppression for improved detection of circulating tumor DNA. Nat Biotechnol 34:547-55
Chabon, Jacob J; Simmons, Andrew D; Lovejoy, Alexander F et al. (2016) Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nat Commun 7:11815
Chaudhuri, Aadel A; Binkley, Michael S; Osmundson, Evan C et al. (2015) Predicting Radiotherapy Responses and Treatment Outcomes Through Analysis of Circulating Tumor DNA. Semin Radiat Oncol 25:305-12
Gentles, Andrew J; Bratman, Scott V; Lee, Luke J et al. (2015) Integrating Tumor and Stromal Gene Expression Signatures With Clinical Indices for Survival Stratification of Early-Stage Non-Small Cell Lung Cancer. J Natl Cancer Inst 107:
Kurtz, David M; Green, Michael R; Bratman, Scott V et al. (2015) Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood 125:3679-87
Bratman, Scott V; Newman, Aaron M; Alizadeh, Ash A et al. (2015) Potential clinical utility of ultrasensitive circulating tumor DNA detection with CAPP-Seq. Expert Rev Mol Diagn 15:715-9
Newman, Aaron M; Bratman, Scott V; Stehr, Henning et al. (2014) FACTERA: a practical method for the discovery of genomic rearrangements at breakpoint resolution. Bioinformatics 30:3390-3
Newman, Aaron M; Bratman, Scott V; To, Jacqueline et al. (2014) An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med 20:548-54
Feng, Weiguo; Gentles, Andrew; Nair, Ramesh V et al. (2014) Targeting unique metabolic properties of breast tumor initiating cells. Stem Cells 32:1734-45